Pacific Edge reports decline in Cxbladder test volumes

Cancer diagnostics company Pacific Edge has reported a decline in Cxbladder test volumes for the three months to September 2025.

The company attributed the decrease to the disruption caused by the transition of US customers from the Detect test to the Triage test, as well as the additional administrative processes faced by healthcare payers and clinicians after the loss of Medicare coverage in April 2025.

Total laboratory throughput in the second quarter of 2026 fell 9% to 6,286 tests, with a 13.1% decrease in US test volumes.

However, Pacific Edge said it successfully concluded the migration to Triage and Triage Plus, which now account for 82% of tests processed at its US laboratory.

The company also reported an improvement in its sales force efficiency metric, but a decline in the number of ordering clinicians.